Systematic Literature Review of the Global Incidence and Prevalence of Myelodysplastic Syndrome and Acute Myeloid Leukemia | Semantic Scholar. https://www.semanticscholar.org/paper/Systematic-Literature-Review-of-the-Global-and-of-Lubeck-Danese/3618fb1ed8a1d9cf79c1d3731ba24dc48b04d1d7

The Global Incidence And Prevalence Of Acute Myeloid Leukemia Over The Next Ten Years (2017–2027). | Journal of Cancer Research & Therapeutics | EBSCOhost. https://openurl.ebsco.com/EPDB%3Agcd%3A3%3A53859/detailv2?sid=ebsco%3Aplink%3Ascholar&id=ebsco%3Agcd%3A127250837&crl=c

Strom SS, Oum R, Elhor Gbito KY, Garcia-Manero G, Yamamura Y. De novo acute myeloid leukemia risk factors: a Texas case-control study. Cancer. 2012;118(18):4589–96.

Article  PubMed  Google Scholar 

Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States - PubMed]. https://pubmed.ncbi.nlm.nih.gov/30268525/

Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood J Am Soc Hematol. 2017;129(4):424–47.

Google Scholar 

Outcomes and health care utilization of older patients with acute myeloid leukemia – PubMed. https://pubmed.ncbi.nlm.nih.gov/32713804/

Mohamed Jiffry MZ, Kloss R, Ahmed-Khan M, Carmona-Pires F, Okam N, Weeraddana P, et al. A review of treatment options employed in relapsed/refractory AML. Hematol Amst Neth. 2023;28(1):2196482.

Google Scholar 

Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345–77.

Article  PubMed  Google Scholar 

Stein EM. IDH inhibitors in acute myeloid leukemia and myelodysplastic syndrome. Clin Adv Hematol Oncol HO. 2021;19(9):556–8.

Google Scholar 

A review of FLT3 inhibitors in acute myeloid leukemia – PubMed. https://pubmed.ncbi.nlm.nih.gov/34774343/

Stomper J, Rotondo JC, Greve G, Lübbert M. Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies. Leukemia. 2021;35(7):1873–89.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rose D, Haferlach T, Schnittger S, Perglerová K, Kern W, Haferlach C. Subtype-specific patterns of molecular mutations in acute myeloid leukemia. Leukemia. 2017;31(1):11–7.

Article  CAS  PubMed  Google Scholar 

DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378(25):2386–98.

Article  CAS  PubMed  Google Scholar 

Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia – PubMed. https://pubmed.ncbi.nlm.nih.gov/35443108/

Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kantarjian HM, Roboz GJ, Kropf PL, Yee KWL, O’Connell CL, Tibes R, et al. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. Lancet Oncol. 2017;18(10):1317–26.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission – PubMed. https://pubmed.ncbi.nlm.nih.gov/33369355/

Nixdorf D, Sponheimer M, Berghammer D, Engert F, Bader U, Philipp N, et al. Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML. Leukemia. 2023;37(6):1298–310.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kasakovski D, Xu L, Li Y. T cell senescence and CAR-T cell exhaustion in hematological malignancies. J Hematol Oncol. 2018;11(1):91.

Article  PubMed  PubMed Central  Google Scholar 

Lamble AJ, Kosaka Y, Laderas T, Maffit A, Kaempf A, Brady LK, et al. Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia. Proc Natl Acad Sci USA. 2020;117(25):14331–41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Toffalori C, Zito L, Gambacorta V, Riba M, Oliveira G, Bucci G, et al. Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. Nat Med. 2019;25(4):603–11.

Article  CAS  PubMed  Google Scholar 

Fiorenza S, Turtle CJ. CAR-T cell therapy for acute myeloid leukemia: preclinical rationale, current clinical progress, and barriers to success. BioDrugs Clin Immunother Biopharm Gene Ther. 2021;35(3):281–302.

Google Scholar 

Angenendt L, Mikesch JH, Schliemann C. Emerging antibody-based therapies for the treatment of acute myeloid leukemia. Cancer Treat Rev. 2022;108:102409.

Article  CAS  PubMed  Google Scholar 

Daver N, Alotaibi AS, Bücklein V, Subklewe M. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. Leukemia. 2021;35(7):1843–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer – PubMed. https://pubmed.ncbi.nlm.nih.gov/35707528/

The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia – PubMed. https://pubmed.ncbi.nlm.nih.gov/30500073/

Huang J, Tan J, Chen Y, Huang S, Xu L, Zhang Y, et al. A skewed distribution and increased PD-1+Vβ+CD4+/CD8+ T cells in patients with acute myeloid leukemia. J Leukoc Biol. 2019;106(3):725–32.

Article  CAS  PubMed  Google Scholar 

Vadakekolathu J, Rutella S. Escape from T-cell targeting immunotherapies in acute myeloid leukemia. Blood. 2023. https://doi.org/10.1182/blood.2023019961.

Article  PubMed  Google Scholar 

Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy – PubMed. https://pubmed.ncbi.nlm.nih.gov/34663807/

Nieuwenhuis TO, Yang SY, Verma RX, Pillalamarri V, Arking DE, Rosenberg AZ, et al. Consistent RNA sequencing contamination in GTEx and other data sets. Nat Commun. 2020;11(1):1933.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang YH, Lin CC, Hsu CL, Hung SY, Yao CY, Lee SH, et al. Distinct clinical and biological characteristics of acute myeloid leukemia with higher expression of long noncoding RNA KIAA0125. Ann Hematol. 2021;100(2):487–98.

Article  CAS  PubMed  Google Scholar 

Chuang MK, Chiu YC, Chou WC, Hou HA, Tseng MH, Kuo YY, et al. An mRNA expression signature for prognostication in de novo acute myeloid leukemia patients with normal karyotype. Oncotarget. 2015;6(36):39098–110.

Article  PubMed  PubMed Central  Google Scholar 

Lee SH, Chiu YC, Li YH, Lin CC, Hou HA, Chou WC, et al. High expression of dedicator of cytokinesis 1 (DOCK1) confers poor prognosis in acute myeloid leukemia. Oncotarget. 2017;8(42):72250–9.

Article  PubMed  PubMed Central  Google Scholar 

Kuett A, Rieger C, Perathoner D, Herold T, Wagner M, Sironi S, et al. IL-8 as mediator in the microenvironment-leukaemia network in acute myeloid leukaemia. Sci Rep. 2015;17(5):18411.

Article  Google Scholar 

Herold T, Jurinovic V, Batcha AMN, Bamopoulos SA, Rothenberg-Thurley M, Ksienzyk B, et al. A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia. Haematologica. 2018;103(3):456–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Herold T, Metzeler KH, Vosberg S, Hartmann L, Röllig C, Stölzel F, et al. Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis. Blood. 2014;124(8):1304–11.

Article  CAS  PubMed  Google Scholar 

Li Z, Herold T, He C, Valk PJM, Chen P, Jurinovic V, et al. Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(9):1172–81.

Article  CAS  Google Scholar 

The sva package for removing batch effects and other unwanted variation in high-throughput experiments – PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3307112/

Vexler A, Gao X, Zhou J. How to implement signed-rank wilcox test () type procedures when a center of symmetry is unknown. Comput Stat Data Anal. 2023;184:107746.

Article  Google Scholar 

Team RC. R: a language and environment for statistical computing. Vienna: R Core team; 2021.

Google Scholar 

Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation. 2021. https://doi.org/10.1016/j.xinn.2021.100141.

Article  PubMed  PubMed Central  Google Scholar 

Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, et al. The STRING database in 2023: protein–protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2023;51(D1):D638–46.

Article  CAS  PubMed  Google Scholar 

Legeay M, Doncheva NT, Morris JH, Jensen LJ. Visualize omics data on networks with Omics visualizer, a cytoscape app. F1000Research. 2020. https://doi.org/10.1268/f1000research.22280.1.

Article  PubMed  PubMed Central  Google Scholar 

Zeng Z, Gao Y, Li J, Zhang G, Sun S, Wu Q, et al. Violations of proportional hazard assumption in Cox regression model of transcriptomic data in TCGA pan-cancer cohorts. Comput Struct Biotechnol J. 2022;20:496–507.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pawar A, Chowdhury OR, Salvi O. A narrative review of survival analysis in oncology using R. Cancer Res Stat Treat. 2022;5(3):554–61.

Article  Google Scholar